Quick Answer
Greenwich LifeSciences, Inc. reported Stockholders Equity of $2.53 million for fiscal year 2024.
Greenwich LifeSciences, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2024 | $2.53M | -62.2% |
| 2023 | $6.70M | -49.3% |
| 2022 | $13.21M | -50.8% |
| 2021 | $26.83M | -2.9% |
| 2020 | $27.63M | +2146.1% |
| 2019 | -$1.35M | +86.7% |
| 2018 | -$10.12M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.18M | -56.1% | +51.8% |
| June 30, 2025 | $1.44M | -75.5% | +9.7% |
| March 31, 2025 | $1.31M | -74.4% | -48.2% |
| December 31, 2024 | $2.53M | -62.2% | -49.1% |
| September 30, 2024 | $4.98M | -43.7% | -15.2% |
| June 30, 2024 | $5.88M | -44.8% | +14.7% |
| March 31, 2024 | $5.12M | -56.2% | -23.6% |
| December 31, 2023 | $6.70M | -49.3% | -24.3% |
- Greenwich LifeSciences, Inc. showed a decrease of -62.2% in Stockholders Equity compared to the prior fiscal year.
- Over the 2018–2024 period, Greenwich LifeSciences, Inc.’s stockholders equity has grown by 125.0% (from -$10.12 million to $2.53 million).
- The most recent figure is from Greenwich LifeSciences, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: